信达生物Strategic partnership with Takeda to de

招银国际

10/23

一、战略合作背景与意义Innovent Biologics(1801HK)与Takeda达成了一项全球战略合作伙伴关系，旨在共同开发多款关键的肿瘤学资产，包括IBI363(PD-1/IL-2)、IBI343(CLDN18.2ADC)和潜在的IBI3001(EGFR/B7H3ADC)。该合作不仅有助于扩展Innovent的全球足迹，还加强了Takeda在实体瘤领域的研发管线。根据协议，Takeda将...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577323198"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577323198\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577323198?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-23 11:15","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2577323198","market":"hk","top_or_hot":-1,"title":"信达生物Strategic partnership with Takeda to de","media":"招银国际","content":"<div>\n<p>一、战略合作背景与意义Innovent Biologics(1801HK)与Takeda达成了一项全球战略合作伙伴关系，旨在共同开发多款关键的肿瘤学资产，包括IBI363(PD-1/IL-2)、IBI343(CLDN18.2ADC)和潜在的IBI3001(EGFR/B7H3ADC)。该合作不仅有助于扩展Innovent的全球足迹，还加强了Takeda在实体瘤领域的研发管线。根据协议，Takeda将...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102311304294d8e06b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信达生物Strategic partnership with Takeda to de</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信达生物Strategic partnership with Takeda to de\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-23 11:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102311304294d8e06b&s=b><strong>招银国际</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一、战略合作背景与意义Innovent Biologics(1801HK)与Takeda达成了一项全球战略合作伙伴关系，旨在共同开发多款关键的肿瘤学资产，包括IBI363(PD-1/IL-2)、IBI343(CLDN18.2ADC)和潜在的IBI3001(EGFR/B7H3ADC)。该合作不仅有助于扩展Innovent的全球足迹，还加强了Takeda在实体瘤领域的研发管线。根据协议，Takeda将...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102311304294d8e06b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102311304294d8e06b&s=b","article_id":"2577323198","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102311304294d8e06b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2577323198","pubTimestamp":1761189316,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"根据协议，Takeda将主导IBI363的全球开发，而Innovent则承担40%的开发成本。对于IBI3001，Takeda拥有选择权以获得其国际市场授权。截至2025年6月，Innovent拥有21亿美元的现金储备，为其全球扩张提供了坚实的财务支撑。此次合作将进一步丰富Takeda的产品组合，尤其是在下一代免疫肿瘤学资产方面。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1583":"高瓴概念","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","01801":"信达生物"},"translate_title":"Innovent Bio Strategic partnership with Takeda to de","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1.5},"content_text":"一、战略合作背景与意义Innovent Biologics(1801HK)与Takeda达成了一项全球战略合作伙伴关系，旨在共同开发多款关键的肿瘤学资产，包括IBI363(PD-1/IL-2)、IBI343(CLDN18.2ADC)和潜在的IBI3001(EGFR/B7H3ADC)。该合作不仅有助于扩展Innovent的全球足迹，还加强了Takeda在实体瘤领域的研发管线。根据协议，Takeda将主导IBI363的全球开发，而Innovent则承担40%的开发成本。同时，两家公司将在美国共同商业化IBI363，并按比例分享收益。二、财务条款与估值分析此次交易包括12亿美元的首付款，其中包含对Innovent的1亿美元股权投资，每股价格为112.56港元。此外，还有可能实现高达114亿美元的里程碑付款及额外版税收入。基于这些条款，CMBIGM上调了Innovent的目标价至110.62港元，维持买入评级。分析师使用DCF模型进行估值，假设加权平均资本成本(WACC)为9.5%，终端增长率为4.0%。三、产品管线进展IBI363(PD-1/IL-2)已在免疫疗法耐药性非小细胞肺癌(NSCLC)中显示出优异的无进展生存期(PFS)和生存获益，并计划在中国和美国启动III期临床试验。IBI343(CLDN18.2ADC)已进入III期临床试验阶段，适应症为晚期胰腺癌(PDAC)和胃癌(GC)，并有望在全球范围内开展进一步研究。对于IBI3001(EGFR/B7H3ADC)，Takeda拥有选择权以获得其国际市场授权。四、公司战略转型与市场预期Innovent正致力于从一家专注于中国市场的生物技术公司转型为具有全球研发和商业化能力的综合型制药企业，目标是在2030年前推进至少五种候选药物进入全球III期多区域临床试验(MRCT)。尽管这一过程需要大量投资，但长期来看，若执行得当，公司将获得显著的战略和商业回报。截至2025年6月，Innovent拥有21亿美元的现金储备，为其全球扩张提供了坚实的财务支撑。五、Takeda的受益与未来发展Takeda通过此次合作增强了其在实体瘤治疗领域的研发实力。2024财年，Takeda的总收入达到300亿美元，其中肿瘤业务贡献了37亿美元，主要来自亮丙瑞林(leuprorelin)和呋喹替尼(fruquintinib)等产品。此次合作将进一步丰富Takeda的产品组合，尤其是在下一代免疫肿瘤学资产方面。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}